Chonluten: A Tripeptide Bioregulator with Pulmonary Tropism

Research summary. Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) belonging to the Khavinson short-peptide bioregulator family. It is reported in the source literature to have selective effects on bronchial mucosal tissue, with secondary activity in the gastrointestinal tract. Like other members of its family, it is studied as a candidate modulator of inflammation- and senescence-associated gene expression.

Molecular profile

• Sequence: Glu-Asp-Gly (EDG)
• Molecular formula: C₁₁H₁₇N₃O₈
• Molecular weight: ~319.3 g/mol
• PubChem CID: 194641
• CAS Number: 75007-24-8
• Synonyms: T-34 tripeptide, EDG
• Class: Short peptide bioregulator (Khavinson peptides) — bronchopulmonary tropism

Mechanism of action

Chonluten's proposed mechanism follows the bioregulator framework: cell and nuclear penetration of the unmodified tripeptide, followed by interaction with chromatin and/or specific gene promoter regions to modulate tissue-selective transcription. Reported molecular endpoints include modulation of expression of:

• Stress and inflammation-related genes: c-Fos, HSP70, COX-2, TNF-α
• Antioxidant defence machinery: superoxide dismutase (SOD)
• Cellular proliferation markers in airway epithelium

The reported pattern — attenuation of pro-inflammatory and stress-response gene expression alongside preservation of antioxidant capacity — is consistent across the Khavinson literature for tissue-selective bioregulators.

Preclinical research highlights

Bronchial epithelium and chronic airway inflammation. Cell-culture and rodent studies have reported normalisation of bronchial mucosal architecture and reduction of inflammatory cytokine expression in models relevant to chronic airway inflammation. The proposed application to asthma and chronic obstructive pulmonary disease research rests primarily on these findings.

Hypoxia tolerance. Rodent studies have reported preserved physical performance and reduced markers of oxidative damage in animals exposed to hypoxic conditions following Chonluten administration, attributed in the source literature to upregulation of antioxidant pathways and modulation of HSP70.

Geroprotective claims. Within the broader Khavinson programme, short bioregulator peptides have been reported to extend rodent lifespan and reduce age-related tumour incidence. Chonluten has been included in this body of work as a respiratory-tropic example, though most of the lifespan-extension data derive from experiments with related family members and longer-acting bioregulator complexes.

Gastrointestinal effects. A smaller body of work has explored secondary activity of Chonluten in gastrointestinal cell preparations, with reported attenuation of inflammatory gene expression broadly consistent with the pulmonary findings. Translation to defined GI inflammatory disease models has not been extensively characterised.

Limitations of the evidence base

Chonluten shares the methodological caveats common to the Khavinson family:

• The supporting literature originates predominantly from a single research programme.
• The proposed direct DNA/chromatin engagement mechanism for an unmodified tripeptide remains controversial in mainstream peptide pharmacology.
• Most outcomes are from cell-culture and rodent endpoints; functional translational outcomes in independent laboratories are limited.
• No registered Phase 2 or Phase 3 clinical trials of Chonluten appear in major Western trial registries.

Position within the bioregulator family

Chonluten functions as the bronchopulmonary counterpart to other tissue-targeted bioregulators in the Khavinson programme — notably Bronchogen, which is the more frequently referenced lung-tropic bioregulator. The two peptides differ in sequence (Bronchogen: Ala-Glu-Asp-Leu, AEDL; Chonluten: Glu-Asp-Gly, EDG) and have somewhat distinct reported gene-modulation profiles, though the broader functional category overlaps. They are sometimes studied in parallel within respiratory-research preparations.

Current research status

Chonluten remains an investigational research peptide. It is not approved as a therapeutic by any major regulatory authority. Within research contexts it serves as:

• A reference compound for tissue-selective short-peptide bioregulator studies
• A candidate modulator in airway inflammation and oxidative stress models
• A geroprotective candidate within the broader Khavinson research framework

Key takeaways for researchers

• Chonluten is a tripeptide (Glu-Asp-Gly) bioregulator with reported tropism for bronchial mucosa and the broader pulmonary system.
• Its proposed mechanism involves direct chromatin interaction and tissue-selective transcriptional modulation of stress, inflammation, and antioxidant gene expression.
• Reported preclinical effects centre on airway epithelium, hypoxia tolerance, and antioxidant defence in rodent models.
• The supporting literature is concentrated in a single research programme; independent validation is limited.
• Chonluten is not an approved therapeutic.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI, et al. Short peptides stimulate cell regeneration: from theory to clinical practice. Bulletin of Experimental Biology and Medicine. 2014;156(3):283–289.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Chonluten is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.